| Agent |
Mechanism |
ClinicalTrials.gov Identifier |
Principal Investigator |
N° of Patients |
Dose |
| GEFITINIB |
TKI EGFR |
Phase 2 |
Loehrer PJ, MD |
26 (7TC) |
250 mg daily |
| ERLOTINIB |
TKI EGFR |
NCT00369889 (plus Bevacizumab)
(Phase 2) |
Loehrer PJ, MD |
18 (7TC) |
150 mg p.o. |
| NCT01306045 (Pilot Study)
(Phase 2) |
Gula U, MD |
Recruiting |
150 mg p.o. |
| CETUXIMAB |
EGFR antibody |
NCT01025089 (plus chemotherapy CAP)
(Phase 2) ONGOING |
James Huang, MD |
Recruiting |
250 mg/m2 weekly |
| IMATINIB |
TKI KIT, Bcr-Abl, and PDGFR |
Phase 2 |
Giaccone G, MD |
7 (5 TC) |
600 mg p.o. daily |
| Phase 1 |
Salter JT, MD |
11 TC |
600 mg p.o. daily |
| Phase 2 |
Palmieri G, MD |
15 (3 TC) |
400 mg p.o. daily |
| NCT00314873 (Phase 1) |
Loehrer PJ, MD |
11 TC |
600 mg qd q 21 |
| SUNITINIB |
TKI VEGFR1-3, FMS-like TK3, c-KIT, PDGFR, FLT-3, RET-receptor and CSF1 |
NCT01621568 Phase 2
ONGOING |
Ragan A, MD |
Ragan A, MD |
50 mg daily |
| SU14813 |
TKI VEGFR2, PDGFR,
c-KIT, FLT-3 |
NCT00982267 (Phase 1) |
Pfizer |
4 |
Escalating doses from 50 to 250 mg daily |
| MOTESANIB
(AM 706) |
TKI KIT, VEGFR -1, -2, -3 and PDGFR |
NCT00093873 (Phase 1) |
Amgen |
1 |
Escalating doses from 50 to 175 mg daily |
| SARACATINIB
(AZD0530) |
Src non-receptor tyrosine kinase inhibitor |
NCT00718809 (Phase 2) |
P.Loeher, MD |
21 (7TC) |
175 mg daily |
| EVEROLIMUS |
mTOR inhibitor |
NCT01563354
(Phase 2) |
Novartis |
Recruiting |
10 mg p.o. daily |
| CIXUTUMUMAB
(IMC-A12) |
IGF-1R antibody |
NCT00965250
(Phase 2) |
Giaccone G, MD |
49 (12TC) |
20 mg/kg iv q21 |
| FIGITUMUMAB
(CP-751.871) |
Phase 2 |
Haluska P, MD |
1 |
dose escalation from 3 to 20 mg/kg iv q21 |
| BEVACIZUMAB |
VEGFR antibody |
NCT00369889 (Plus Erlotinib)
(Phase 2) |
P. J Loehrer, MD |
18 (7TC) |
15 mg/kg iv q21 |
| AFLIBERCEPT
(AVE0005) |
TKI VEGFR-A,
VEGFR-B and PIGF |
NCT00545246 with docetaxel
(Phase 1) |
Sanofi |
1 |
dose escalation 2, 4, 6, 7, 9 mg/kg iv |
| BELINOSTAT
(PDX101 |
Pan-HDAC inhibitor |
NCT00589290 (Phase 2) |
Giaccone G, MD |
41 (16 TC) |
1000mg/m2
1-5 days q21 |
| FR901228 (DP)
and FLA |
HDAC inhibitor and
CDK inhibitor |
NCT01100944 in combination with PAC
(Phase 1/2)
ONGOING |
Rajan A, MD |
26 |
four dose levels and dose escalations |
| DECITABINE |
DNMT inhibitor |
(Phase 1) |
Stewart DJ |
4 |
dose escalation 2,5-10 mg/m2 and 8,12,15,20 mg/m2 |
| MILCICLIB MALEATE
(PHA-848125AC |
CDK2, CDK1, CDK4
and TRKA Inhibitor |
NCT01011439 (Phase 2)
ONGOING |
Weiss G, Besse B, Mazieres J, Novello S, Rajan A, Garassino MC, MD |
Recruiting TC |
150 mg/daily |
| NCT01301391 (Phase 2)
ONGOING |
Rajan A and Garassino, MD |
Recruiting Thymomas |
150 mg daily 1-7 |
| Octreotide-LAR |
NCT00990535 (HIDONET)
(Phase 2) ONGOING |
Colao A, MD |
|
30 mg sc/daily |
| Octreotide +/- prednisone |
NCT00003283 (Phase 2) |
Loehrer PJ, MD |
38 (5 TC) |
1.5 mg/daily subcut |
| Octreotide-LAR NCT00332969 (Phase 2)
ONGOING |
NCT00332969 (Phase 2)
ONGOING |
Novartis |
25 |
30 mg sc/daily |
|
